41 results
8-K
EX-1.1
CGTX
Cognition Therapeutics Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:07pm
or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products, asbestos
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
4 Jan 24
Other Events
4:21pm
Powerful scientific validation of σ-2 science The Right Target ✓ Targeting toxic stressors: Aβ and α-synuclein oligomers and ROS in neurodegenerative … peer-reviewed publications and NIA grant process Sigma-2 (σ-2) complex regulates cellular damage response processes CT1812 Protects Neurons from Toxic
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
12 Sep 23
Other Events
7:00am
Targets oligomers, a pathogenic form of amyloid plaques produced early in AD Blocks toxic oligomer binding, displaces bound oligomers - protecting … mechanism of action within the established amyloid cascade CT1812 Protects Neurons from Toxic Stressors Represents potential breakthrough: Treat Alzheimer’s
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
24 Aug 23
Regulation FD Disclosure
7:00am
in blocking toxic oligomer binding and displacing bound oligomers - High degree of blood brain barrier penetration, thus reaches its target - Disease
8-K
EX-99.1
91u6krw
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
EX-99.1
johulg
19 Apr 23
Developing disease-modifying medicines for degenerative disorders Analyst Breakfast April 2023
7:30am
8-K
EX-10.1
ar2rs1lv1v9 bb
23 Dec 22
Entry into a Material Definitive Agreement
4:24pm
S-3
EX-1.2
1cce22n3y623p
23 Dec 22
Shelf registration
4:16pm
8-K
EX-99.1
2ni45supdra6iyro
16 Nov 22
Developing disease - modifying medicines for degenerative disorders November 2022
5:18pm
8-K
EX-1.1
j3cj7j7dvxir2pvxaik
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
8-K
EX-99.1
93g75o8
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
424B4
acvmu
14 Nov 22
Prospectus supplement with pricing info
6:02am
DRS
go7fo
20 Oct 22
Draft registration statement
12:00am
10-K
ejktp5 vr7k
30 Mar 22
Annual report
7:40am
8-K
EX-99.1
z85z0bbo
15 Mar 22
Regulation FD Disclosure
9:32am
10-Q
s0sfy6wxdaprkg2afu
17 Nov 21
Quarterly report
5:15pm